In supporting the former scenario, a current study described that high MK expression in mouse melanomas can trigger resistance to immune checkpoint blockade strategies through targeting PD-1/PD-L1, whereas the ablation of MK can re-sensitize cancers to the immunotherapies [33]. The gene discussed is MDK; the disease is melanoma.